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OBJECTIVE — Coffee consumption has been associated with lower risk of type 2 diabetes.
We evaluated the acute effects of decaffeinated coffee and the major coffee components chloro-
genic acid and trigonelline on glucose tolerance.
RESEARCH DESIGN AND METHODS — We conducted a randomized crossover trial
of the effects of 12 g decaffeinated coffee, 1 g chlorogenic acid, 500 mg trigonelline, and placebo
(1 g mannitol) on glucose and insulin concentrations during a 2-h oral glucose tolerance test
(OGTT) in 15 overweight men.
RESULTS — Chlorogenic acid and trigonelline ingestion signiﬁcantly reduced glucose (0.7
mmol/l, P  0.007, and 0.5 mmol/l, P  0.024, respectively) and insulin (73 pmol/l, P 
0.038,and117pmol/l,P0.007)concentrations15minfollowinganOGTTcomparedwith
placebo. None of the treatments affected insulin or glucose area under the curve values during
the OGTT compared with placebo.
CONCLUSIONS — Chlorogenic acid and trigonelline reduced early glucose and insulin
responses during an OGTT.
Diabetes Care 32:1023–1025, 2009
I
n prospective cohort studies, higher
coffee consumption has been associ-
atedwithalowerriskoftype2diabetes
(1,2). Associations have been similar for
caffeinated and decaffeinated coffee
(1,3–5), suggesting that coffee compo-
nentsotherthancaffeinehavebeneﬁcial
effectsonglucosehomeostasis.Coffeeis
a major source of the phenolic com-
pound chlorogenic acid (6) and the vi-
tamin B3 precursor trigonelline (7),
whichhavebeenshowntoreduceblood
glucose concentrations in animal stud-
ies (5–8). This is the ﬁrst study to in-
vestigatetheacuteeffectsofchlorogenic
acid and trigonelline on glucose toler-
ance in humans.
RESEARCH DESIGN AND
METHODS— Fifteen male, healthy,
nonsmoking, overweight (BMI 25.0–
35.0 kg/m
2) coffee consumers were en-
rolled. All subjects provided written
informed consent.
Subjects were randomly assigned
to a unique treatment order through
computer-generated randomization by
the pharmacy. Four supplements were
tested in this crossover trial: 12 g decaf-
feinated coffee (Nescafe ´ Gold, Nestle ´, the
Netherlands),1gchlorogenicacid(Sigma
Aldrich, Switzerland), 500 mg trigonel-
line (Sigma Aldrich), and 1 g mannitol as
placebo (Spruyt Hillen Bufa, the Nether-
lands). Based on laboratory measure-
ments (9,10), the decaffeinated coffee
used in our study provided 264 mg chlo-
rogenic acid and 72 mg trigonelline. All
supplements were dissolved in 270 ml
water, and treatments except for decaf-
feinated coffee were double blind. Start-
ing 1 week before the trial, participants
wererequestedtorestricttheircoffeecon-
sumption to maximally one cup per day,
and on the days before each study visit no
coffee was allowed.
The study consisted of four visits sep-
aratedbyatleast6days.Duringeachvisit,
participants ingested one of the supple-
ments 30 min before a 75-g oral glucose
tolerance test (OGTT). Seven venous
bloodsamplesweretakenviaacannulain
the antecubital vein on each visit follow-
inganovernightfast.Theﬁrstbloodsam-
ple was taken 30 min before the start of
the OGTT, immediately followed by in-
gestion of the supplement. The second
blood sample was taken just before the
OGTT, and the other samples were taken
15,30,60,90,and120minafterthestart
of the OGTT.
Laboratory analyses were conducted
at the VU University Medical Center.
Plasma glucose concentrations were mea-
sured using the glucose hexokinase
method with an interassay coefﬁcient of
variation (CV) of 1.3% (Roche Diagnos-
tics, Mannheim, Germany). Serum insu-
lin concentrations were measured using
an immunoradiometric assay (Bayer Di-
agnostics, Mijdrecht, the Netherlands);
the intra-assay CV was 4%, and the inter-
assay CV was 8%.
The area under the curve values for
glucose and insulin were calculated using
the trapezoidal method. Main treatment
effects were analyzed using linear mixed
regression models. Comparisons of mean
glucose and insulin concentrations for in-
dividual time points were conducted us-
ingpairedttests.Alltestsweretwo-sided,
and P values 0.05 were considered sta-
tistically signiﬁcant. Analyses were con-
ducted using SPSS (version 15.0).
RESULTS— The participants had a
mean  SD age of 39.9  16.5 years and
a mean BMI of 27.6  2.2 kg/m
2. There
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adverse events were reported.
Glucose concentrations tended to be
lower after chlorogenic acid ingestion
compared with those after placebo (Table
1), but this difference was only statisti-
cally signiﬁcant 15 min after the start of
the OGTT (difference 0.69 mmol/l [95%
CI 0.22–1.17]; P  0.007). In addition,
the mean insulin concentration was 6.6
pmol/l (95% CI 0.11–13.0; P  0.047)
lower at the start of the OGTT and 73.3
pmol/l (4.7–142.0; P  0.038) lower at
15 min for chlorogenic acid compared
with placebo.
Trigonelline also resulted in signiﬁ-
cantly lower glucose (0.51 mmol/l
[95% CI 0.95 to 0.08]; P  0.024)
and insulin (117.0 pmol/l [196.5 to
37.4];P0.007)concentrationsat15
min after the start of the OGTT com-
pared with placebo. Decaffeinated cof-
fee did not signiﬁcantly change mean
glucose or insulin concentrations at any
of the time points following the OGTT,
although the insulin concentration
tended to be lower at 15 min. None of
the treatments signiﬁcantly changed the
insulin or glucose area under the curve
values (Table 1).
CONCLUSIONS— In this random-
ized crossover trial in healthy men, chlo-
rogenicacidandtrigonellineingestionled
to signiﬁcantly lower glucose and insulin
concentrations 15 min after an oral glu-
cose load but did not signiﬁcantly reduce
the OGTT insulin and glucose areas un-
der the curve compared with placebo.
Battram et al. (11) found a signiﬁ-
cantly lower OGTT glucose area under
the curve after decaffeinated coffee com-
pared with that after placebo, but no sig-
niﬁcant effect was found in the current
studyortwosmallerpreviousstudies(12,
13). Further research is needed to eluci-
date whether these differences in study
results are due to chance or to differences
in study methods. Trigonelline (5) and
chlorogenic acid (6–8) have been shown
toreducebloodglucoseconcentrationsin
rats, but data in humans are sparse. In a
study of 10 diabetic patients, intake of
500 mg trigonelline had mixed and non-
signiﬁcant effects on glucose concentra-
tions (9).
Several mechanisms have been sug-
gested for effects of chlorogenic acid on
glucose metabolism. In vitro, chloro-
genic acid has been shown to inhibit
-glucosidase and glucose-6-phospha-
tase, suggesting that it may delay intes-
tinal glucose uptake (8,14). This effect
could also reduce postprandial hyper-
glycemia through improved glucose-
induced insulin secretion as a result of
increased glucagon-like peptide-1 se-
cretion (12). Inhibition of glucose-6-
phosphatase could also reduce hepatic
glucose output (15), which may have
contributed to the reduction of fasting
insulinconcentrationsthatwefoundfor
chlorogenic acid.
In our study, the multiple tests con-
ducted for different time points increased
the likelihood of chance ﬁndings, and
conﬁrmation of our results is therefore
needed. In addition, the decaffeinated
coffee supplement contained substan-
tially less chlorogenic acid and trigonel-
line than the doses administered in
isolation, complicating the comparison of
the treatment effects.
In conclusion, chlorogenic acid and
trigonelline reduced early glucose and in-
sulin responses during the OGTT. This
ﬁnding is consistent with the hypothesis
that these compounds contribute to the
putative beneﬁcial effect of coffee on de-
velopment of type 2 diabetes.
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